D
D. Konatham
Publications - 9
Citations - 921
D. Konatham is an academic researcher. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 7, co-authored 9 publications receiving 921 citations.
Papers
More filters
Journal ArticleDOI
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands,S. Rao,Brian E. Dixon,Patrick K. Mitchell,Malini B. DeSilva,Stephanie A. Irving,Ned Lewis,Karthik Natarajan,Edward Stenehjem,Shaun J. Grannis,Jungmi Han,Charlene McEvoy,Toan C. Ong,Allison L. Naleway,Sara E. Reese,Peter J. Embi,Kristin Dascomb,Nicola P. Klein,E. Griggs,D. Konatham,Anupam B. Kharbanda,Duck-Hye Yang,William F. Fadel,Nancy Grisel,Kristin Goddard,Palak Patel,I-Chia Liao,Rebecca Birch,Nimish Valvi,Sue Reynolds,Julie Arndorfer,Ousseny Zerbo,M. Dickerson,Kempapura Murthy,Jeremiah Williams,Catherine H Bozio,Lenee Blanton,Jennifer R. Verani,Stephanie J. Schrag,Alexandra F. Dalton,Mehiret Wondimu,Ruth Link-Gelles,Eduardo Azziz-Baumgartner,Michelle A. Barron,Manjusha Gaglani,Mark Thompson,Bruce Fireman +46 more
TL;DR: VE after receipt of a third dose was higher than that after a second dose; however, VE waned with increasing time since vaccination, and VE was generally higher for protection against hospitalizations than against ED/UC visits.
Journal ArticleDOI
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Mark Thompson,Karthik Natarajan,Stephanie A. Irving,Elizabeth Rowley,E. Griggs,Manjusha Gaglani,Nicola P. Klein,Shaun J. Grannis,Malini B. DeSilva,Edward Stenehjem,Sara E. Reese,M. Dickerson,Allison L. Naleway,Jungmi Han,D. Konatham,Charlene McEvoy,S. Rao,Brian E. Dixon,Kristin Dascomb,Ned Lewis,M. Levy,Palak Patel,I-Chia Liao,Anupam B. Kharbanda,Michelle A. Barron,William F. Fadel,Nancy Grisel,Kristin Goddard,Duck-Hye Yang,Mehiret Wondimu,Kempapura Murthy,Nimish Valvi,Julie Arndorfer,Bruce Fireman,M. Dunne,Peter J. Embi,Eduardo Azziz-Baumgartner,Ousseny Zerbo,Catherine H Bozio,Sue Reynolds,Jill M. Ferdinands,Jeremiah Williams,Ruth Link-Gelles,Stephanie J. Schrag,Jennifer R. Verani,Sarah Ball,Toan C. Ong +46 more
TL;DR: The highest estimates of VE against COVID-19-associated ED and UC encounters or hospitalizations during both Delta- and Omicron-predominant periods were among adults who received a third dose of mRNA vaccine, and all unvaccinated persons should get vaccinated as soon as possible.
Journal ArticleDOI
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
Nicola P. Klein,Melissa S. Stockwell,Maria Demarco,Manjusha Gaglani,Anupam B. Kharbanda,Stephanie A. Irving,S. Rao,Shaun J. Grannis,Kristin Dascomb,Kempapura Murthy,Elizabeth Rowley,Alexandra F. Dalton,Malini B. DeSilva,Brian E. Dixon,Karthik Natarajan,Edward Stenehjem,Allison L. Naleway,Ned Lewis,Toan C. Ong,Palak Patel,D. Konatham,Peter J. Embi,Sara E. Reese,Jungmi Han,Nancy Grisel,Kristin Goddard,Michelle A. Barron,M. Dickerson,I-Chia Liao,William F. Fadel,Duck-Hye Yang,Julie Arndorfer,Bruce Fireman,E. Griggs,Nimish Valvi,C. Hallowell,Ousseny Zerbo,Sue Reynolds,Jill M. Ferdinands,Mehiret Wondimu,Jeremiah Williams,Catherine H Bozio,Ruth Link-Gelles,Eduardo Azziz-Baumgartner,Stephanie J. Schrag,Mark Thompson,Jennifer R. Verani +46 more
TL;DR: VE against laboratory-confirmed COVID-19-associated hospitalization among children aged 5-11 years was 74% 14-67 days after dose 2, with wide CIs that included zero, and in adolescents aged 16-17 years, VE during the Omicron predominant period increased to 81% ≥7 days after a third booster dose.
Journal ArticleDOI
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
Ruth Link-Gelles,M. Levy,Manjusha Gaglani,Stephanie A. Irving,Melissa S. Stockwell,Kristin Dascomb,Malini B. DeSilva,Sara E. Reese,I-Chia Liao,Toan C. Ong,Shaun J. Grannis,Charlene McEvoy,Palak Patel,Nicola P. Klein,E. Hartmann,Edward Stenehjem,Karthik Natarajan,Allison L. Naleway,Kempapura Murthy,S. Rao,Brian E. Dixon,Anupam B. Kharbanda,Akintunde Akinseye,M. Dickerson,Ned Lewis,Nancy Grisel,Jungmi Han,Michelle A. Barron,William F. Fadel,M. Dunne,Kristin Goddard,Julie Arndorfer,D. Konatham,Nimish Valvi,Jon Currey,Bruce Fireman,Chandni Raiyani,Ousseny Zerbo,C. Sloan-Aagard,Sarah Ball,Mark Thompson,Mark W Tenforde +41 more
TL;DR: Estimates of COVID-19 vaccine effectiveness (VE) can be reduced by newly emerging variants or sublineages that evade vaccine-induced immunity, protection from previous SARS-CoV-2 infection in unvaccinated persons (2), or increasing time since vaccination (3).
Journal ArticleDOI
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
Mark W Tenforde,Zachary A. Weber,Karthik Natarajan,Nicola P. Klein,Anupam B. Kharbanda,Edward Stenehjem,Peter J. Embi,Sara E. Reese,Allison L. Naleway,Shaun J. Grannis,Malini B. DeSilva,Toan C. Ong,Manjusha Gaglani,Jungmi Han,M. Dickerson,Bruce Fireman,Kristin Dascomb,Stephanie A. Irving,Gabriela Vazquez-Benitez,S. Rao,D. Konatham,Palak Patel,Kristin E. Schrader,Ned Lewis,Nancy Grisel,Charlene McEvoy,Kempapura Murthy,E. Griggs,Elizabeth Rowley,Ousseny Zerbo,Julie Arndorfer,M. Dunne,Kristin Goddard,Caitlin E. Ray,Yang Zhang,Julius Timbol,M. N. Najdowski,Duck-Hye Yang,John Hansen,Sarah Ball,Ruth Link-Gelles +40 more
TL;DR: In this article , the authors evaluated vaccine effectiveness (VE) of a bivalent mRNA booster dose (after 2, 3, or 4 monovalent doses) compared with no previous vaccination and previous receipt of 2, three, or four only mRNA vaccine doses, among immunocompetent adults with an emergency department/urgent care (ED/UC) encounter or hospitalization for a COVID-19-like illness.